NTRK1 and neoplasm: NTRK1, therefore, produces a wider range of TrkA protein isoforms than previously considered, with tumour-suppressing and oncogenic potential [14,15,24,25], and TrkAIII represents the pathological equivalent of a previously reported engineered oncogenic TrkA D4-deletion mutant [19].